KR860000870A - 신규 항고혈압제 및 항앙기나제와 그 제조방법 - Google Patents

신규 항고혈압제 및 항앙기나제와 그 제조방법 Download PDF

Info

Publication number
KR860000870A
KR860000870A KR1019850005239A KR850005239A KR860000870A KR 860000870 A KR860000870 A KR 860000870A KR 1019850005239 A KR1019850005239 A KR 1019850005239A KR 850005239 A KR850005239 A KR 850005239A KR 860000870 A KR860000870 A KR 860000870A
Authority
KR
South Korea
Prior art keywords
component
group
antianginase
antihypertensive
agent according
Prior art date
Application number
KR1019850005239A
Other languages
English (en)
Inventor
그로쓰 라이너 (외 3)
Original Assignee
에리히 데브리쯔, 요아힘 그렘
바이엘 악티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6241524&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR860000870(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에리히 데브리쯔, 요아힘 그렘, 바이엘 악티엔 게젤샤프트 filed Critical 에리히 데브리쯔, 요아힘 그렘
Publication of KR860000870A publication Critical patent/KR860000870A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

신규 항고혈압제 및 항앙기제니와 그 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 일반식(Ⅰ)의 비대칭 에스테르기를 갖는 디히드로피리딘(성분 A)과 국부 마취작용이 없는 β-블로커(성분 B)를 성분 A 0.1-10중량부와 성분 B10-200중량부의 중량비로 함유하는 항고협압제 및 항앙기나제.
    상기 식중, R1및 R5는 서로 동일하거나 또는 상이한 것으로서, 메틸, 히드록시메틸 또는 시아노기이고, R2및 R4는 항상 서로 상이한 것으로서, 알킬(이 알킬기는 탄소 원자수가 1내지 10개이고, C1-C4알콕시에 의해 임의로 치환됨), 불소, 염소 또는 N-메틸벤젠아미노기이고, R3은 니트로, 염소 및 트리플루오로메틸로 되는 군 중에서 선택된 1 또는 2개의 서로 동일하거나 또는 상이한 치환체이거나, 또는 N-O=N기이다.
  2. 제1항에 있어서, 성분 B로서 아테놀롤, 소탈롤, 티몰롤 및 나돌롤로 되는 군중에서 선택된 β-블로커를 사용함을 특징으로 하는 항고혈압제 및 항앙기나제.
  3. 제1항에 있어서, 성분 A로서 니트렌디핀 또는 니솔디핀을 사용함을 특징으로 하는 항고협압제 및 항앙기나제.
  4. 제1항 및 2항에 있어서, 성분 A와 B를 1 : 2-6의 중량비로 사용함을 특징으로 하는 약제.
  5. 제1항 내지 4항에 있어서, 1일 복용량에 성분 A를 1-100㎎, 성분 B를 1-200㎎함유시킴을 특징으로 하는 약제.
  6. 제1항 내지 4항에 있어서, 1일 복용량에 성분 A를 5-30㎎, 성분 B를 30-80㎎함유시킴을 특징으로 하는 약제.
  7. 제1항 내지 6항에 있어서, 분말제, 과립제, 정제, 캡슐제 또는 당의정 형태의 약제.
  8. 제1항 내지 7항에 있어서, 성분 A와 성분 B를 부형제와 함께, 필요에 따라서 기타 유효 화합물을 첨가하여, 적합한 투여형태로 전환시킴을 특징으로 하는 약제의 제조방법.
  9. 제8항에 있어서, 성분 A를 결정형 또는 무정형으로 사용함을 특징으로 하는 약제의 제조 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850005239A 1984-07-25 1985-07-23 신규 항고혈압제 및 항앙기나제와 그 제조방법 KR860000870A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3427402.2 1984-07-25
DE19843427402 DE3427402A1 (de) 1984-07-25 1984-07-25 Neues kombinationspraeparat, verfahren zu seiner herstellung und seine verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
KR860000870A true KR860000870A (ko) 1986-02-20

Family

ID=6241524

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850005239A KR860000870A (ko) 1984-07-25 1985-07-23 신규 항고혈압제 및 항앙기나제와 그 제조방법

Country Status (12)

Country Link
EP (1) EP0169470A3 (ko)
JP (1) JPS6144816A (ko)
KR (1) KR860000870A (ko)
AU (1) AU576608B2 (ko)
CA (1) CA1255596A (ko)
DE (1) DE3427402A1 (ko)
DK (1) DK338185A (ko)
ES (1) ES8608887A1 (ko)
GR (1) GR851823B (ko)
IL (1) IL75873A (ko)
PT (1) PT80852B (ko)
ZA (1) ZA855584B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3424553A1 (de) * 1984-07-04 1986-01-09 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
DE3447170A1 (de) * 1984-12-22 1986-07-03 Bayer Ag, 5090 Leverkusen Mischung unterschiedlicher dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE3610037A1 (de) * 1986-03-21 1987-09-24 Schering Ag Nifedipinkombinationspraeparat
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2084017B (en) * 1980-09-18 1984-08-22 Sandoz Ltd Pharmaceutical compositions effective against coronary heat disease and hypertension
DE3419131A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung
DE3419130A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Nifedipinkombinationspraeparate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
PT80852A (en) 1985-08-01
GR851823B (ko) 1985-11-26
ES545522A0 (es) 1986-07-16
EP0169470A2 (de) 1986-01-29
IL75873A (en) 1988-11-30
ZA855584B (en) 1986-03-26
JPS6144816A (ja) 1986-03-04
DE3427402A1 (de) 1986-01-30
ES8608887A1 (es) 1986-07-16
AU4528585A (en) 1986-01-30
EP0169470A3 (de) 1988-11-02
DK338185D0 (da) 1985-07-24
PT80852B (pt) 1987-11-30
AU576608B2 (en) 1988-09-01
IL75873A0 (en) 1985-11-29
DK338185A (da) 1986-01-26
CA1255596A (en) 1989-06-13

Similar Documents

Publication Publication Date Title
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
RU95108759A (ru) Фармацевтические соединения
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
DK0533280T3 (da) Ny medicinsk anvendelse af tachykininantagonister
KR880008986A (ko) D 계열 프로스타글란딘, 및 그를 함유하는 정신안정제와 최면제
KR970704435A (ko) 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands)
ATE18765T1 (de) Pharmazeutische zusammenstellungen.
FI961914A (fi) Lyhytvaikutteiset dihydropyridiinit
KR910016697A (ko) 테트라히드로피리딘 유도체
KR920021547A (ko) 아졸 유도체
ES534505A0 (es) Un procedimiento para la preparacion de compuestos de 1, 4-dihidropiridina
KR860000864A (ko) 디히드로피리딘을 함유하는 고상 약제 및 그 제조방법
HUP9801386A2 (hu) Szerotonin 5-HT4 receptor parciális agonistáiként és antagonistáiként alkalmazható indazol-karboxamid-származékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
ES478605A1 (es) Un procedimiento para preparar derivados de flavano.
IL69882A (en) Analgesia-effecting 5-hydroxytryptophan derivatives and pharmaceutical compositions comprising them
KR890014107A (ko) 백금 화학 요법약제
KR860000870A (ko) 신규 항고혈압제 및 항앙기나제와 그 제조방법
AU643290B2 (en) Derivatives of 2-aminoalkyl-5-arylalkyl-1,3-dioxanes, their preparation and their therapeutic application
DE69317418D1 (de) PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON 5HT1 AGONISTISCHEN ALKYL SULPHONAMIDENFüR REKTALE VERABREICHUNGEN
KR870005641A (ko) 고혈압 치료용 조성물
KR890001557A (ko) 약학적 조성물
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
RU2000109298A (ru) Производные 8-азабицикло[3.2.1]октан-3-метанамина в качестве лигандов рецепторов дофамина d2 и d3 и рецепторов серотонина 5ht14 b 5ht2
KR910005860A (ko) 항간질환성 조성물
KR900009640A (ko) 벤족 사제핀 유도체

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid